ICU Medical stock faces recall scrutiny after Q2 results

Published on 10/05/2026 at 10:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ICU Medical stock is tied to two Class II recalls covering 185,688 reservoirs and 163,500,199 administration sets. Q2 revenue reached USD 551.7 million, above USD 533.4 million consensus.

ICUI, US44930G1076, Illustration mit AI erstellt.

ICU Medical (ISIN US44930G1076) was last at USD 159.38 on Nasdaq on October 2, 2026, up 1.40 percent in the session. The latest company issue involves two Class II recalls covering 185,688 CADD reservoirs and 163,500,199 Plum administration sets, according to Simply Wall St on October 3, 2026.

Recalls raise execution pressure

The recalls affect products used across ICU Medical's infusion ecosystem, putting product reliability alongside sales growth in the investor discussion. Simply Wall St said the Plum administration set recall touches the same installed base that supports recurring consumables revenue and margin improvement.

ICU Medical develops and sells infusion therapy and critical care products, including smart pumps, administration sets, connectors and safety software, according to ICU Medical. That product mix makes the scale of the recall relevant beyond a single device line because consumables are connected to hospital workflows and installed equipment.

Q2 revenue beat expectations

ICU Medical reported USD 551.7 million of revenue in Q2 2026, versus USD 533.4 million expected by FactSet, while diluted EPS was USD 0.76, according to Zonebourse on August 6, 2026. The revenue comparison gives the stock a quantified operating counterpoint to the recall risk.

ICU Medical's Q2 revenue was USD 21.5 million above that consensus estimate, a 4.0 percent difference. The company also updated its fiscal 2026 EPS guidance to USD 8.60-9.00 in the same results coverage.

Analyst target stays above price

MarketBeat reported a Moderate Buy consensus from nine analysts on September 10, 2026, with an average 12-month price target of USD 192.80. The target lies 21.0 percent above the October 2 price, while the stock's USD 112.50 to USD 192.85 52-week range places the latest quote 17.4 percent below its yearly high.

MarketBeat also reported that Needham raised its price target from USD 165.00 to USD 187.00 and retained a Buy rating on August 7, 2026. For investors, the central tension is measurable: Q2 revenue exceeded consensus, while quality actions now test the reliability of the consumables platform.

ICUI stock remains below yearly high

ICUI was last at USD 159.38 on Nasdaq on October 2, 2026, with a market capitalization of USD 4.0 billion. The quote stood below the USD 192.85 52-week high, keeping recall execution and the next operating update central to the stock's valuation discussion.